RC108
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for RC108, covering 2025-07-16 to 2025-07-16. Get the full timeline:
Most recent: Clinical Trial Update: A Phase Ⅱ Study of RC108 in Combination With Furmonertinib for the First-line Treatment of EGFR-Mutated Combined MET-Positive Unresectable Locally Advanced or Recurrent Metastatic NSCLC [Phase 2]